Cargando…

The effects of target-controlled infusion of lidocaine undergoing vocal cord polypectomy: A randomized controlled trial (CONSORT compliant)

BACKGROUND: The present study aimed to assess the efficacy and safety of general anesthesia-assisted target-controlled plasma infusion of lidocaine in patients with vocal cord polypectomy using a supporting laryngoscope. METHODS: In total, 80 patients undergoing vocal cord polypectomy using a suppor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, LongYuan, Wu, RuiLan, Cai, Chang, Qi, Yong, Bi, XingHua, Hang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830819/
https://www.ncbi.nlm.nih.gov/pubmed/35147085
http://dx.doi.org/10.1097/MD.0000000000027642
_version_ 1784648358407700480
author Zhou, LongYuan
Wu, RuiLan
Cai, Chang
Qi, Yong
Bi, XingHua
Hang, Qi
author_facet Zhou, LongYuan
Wu, RuiLan
Cai, Chang
Qi, Yong
Bi, XingHua
Hang, Qi
author_sort Zhou, LongYuan
collection PubMed
description BACKGROUND: The present study aimed to assess the efficacy and safety of general anesthesia-assisted target-controlled plasma infusion of lidocaine in patients with vocal cord polypectomy using a supporting laryngoscope. METHODS: In total, 80 patients undergoing vocal cord polypectomy using a supporting laryngoscope were randomly divided into an intervention group and a control group; each group contained 40 subjects: both groups received general anesthesia; subjects in the intervention also received an additional 3 mg/L of lidocaine by target-controlled plasma infusion during induction and maintenance of anesthesia; heart rate (HR) mean arterial pressure (MAP), propofol and urapidil consumption (Uradil, which is a blood pressure drug that blocks alpha-1, is called Urapidi Hydrochloride Injection. It is produced by Germany, the enterprise name is Nycomed Deutschland GmbH, the import drug registration number is H20090715, and it is widely used in China), recovery time, and cough score (measured by Minogue et al's 5-grade scoring method) during extubation, and throat pain score (measured by visual analogue scale,[VAS]) after extubation and adverse events were recorded. RESULTS: Significant differences were observed in HR (P < .05) and MAP (P < .05) immediately after intubation (T2), immediately after the operation starting to support laryngoscope exposure (T3), immediately after operation field adrenergic tampon hemostasis (T4), and 5 minutes after hemostasis (T5) between the 2 groups, and significant differences were also observed in HR (P < .05) before intubation (T1). Moreover, significant differences were observed in propofol consumption (P < .05), urapidil consumption (P < .05), cough score during extubation (P < .05), and throat pain score after extubation (P < .05). However, no significant difference was observed in the recovery time (P > .05). Furthermore, no adverse events were detected in either group. CONCLUSION: The results of this study showed that target-controlled plasma infusion of lidocaine can reduce propofol consumption in patients undergoing vocal cord polypectomy by supporting laryngoscopy, and the hemodynamics are more stable and reduce the coughing reaction in the wake period and throat pain after extubation without adverse events.
format Online
Article
Text
id pubmed-8830819
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-88308192022-02-15 The effects of target-controlled infusion of lidocaine undergoing vocal cord polypectomy: A randomized controlled trial (CONSORT compliant) Zhou, LongYuan Wu, RuiLan Cai, Chang Qi, Yong Bi, XingHua Hang, Qi Medicine (Baltimore) 3300 BACKGROUND: The present study aimed to assess the efficacy and safety of general anesthesia-assisted target-controlled plasma infusion of lidocaine in patients with vocal cord polypectomy using a supporting laryngoscope. METHODS: In total, 80 patients undergoing vocal cord polypectomy using a supporting laryngoscope were randomly divided into an intervention group and a control group; each group contained 40 subjects: both groups received general anesthesia; subjects in the intervention also received an additional 3 mg/L of lidocaine by target-controlled plasma infusion during induction and maintenance of anesthesia; heart rate (HR) mean arterial pressure (MAP), propofol and urapidil consumption (Uradil, which is a blood pressure drug that blocks alpha-1, is called Urapidi Hydrochloride Injection. It is produced by Germany, the enterprise name is Nycomed Deutschland GmbH, the import drug registration number is H20090715, and it is widely used in China), recovery time, and cough score (measured by Minogue et al's 5-grade scoring method) during extubation, and throat pain score (measured by visual analogue scale,[VAS]) after extubation and adverse events were recorded. RESULTS: Significant differences were observed in HR (P < .05) and MAP (P < .05) immediately after intubation (T2), immediately after the operation starting to support laryngoscope exposure (T3), immediately after operation field adrenergic tampon hemostasis (T4), and 5 minutes after hemostasis (T5) between the 2 groups, and significant differences were also observed in HR (P < .05) before intubation (T1). Moreover, significant differences were observed in propofol consumption (P < .05), urapidil consumption (P < .05), cough score during extubation (P < .05), and throat pain score after extubation (P < .05). However, no significant difference was observed in the recovery time (P > .05). Furthermore, no adverse events were detected in either group. CONCLUSION: The results of this study showed that target-controlled plasma infusion of lidocaine can reduce propofol consumption in patients undergoing vocal cord polypectomy by supporting laryngoscopy, and the hemodynamics are more stable and reduce the coughing reaction in the wake period and throat pain after extubation without adverse events. Lippincott Williams & Wilkins 2022-02-11 /pmc/articles/PMC8830819/ /pubmed/35147085 http://dx.doi.org/10.1097/MD.0000000000027642 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 3300
Zhou, LongYuan
Wu, RuiLan
Cai, Chang
Qi, Yong
Bi, XingHua
Hang, Qi
The effects of target-controlled infusion of lidocaine undergoing vocal cord polypectomy: A randomized controlled trial (CONSORT compliant)
title The effects of target-controlled infusion of lidocaine undergoing vocal cord polypectomy: A randomized controlled trial (CONSORT compliant)
title_full The effects of target-controlled infusion of lidocaine undergoing vocal cord polypectomy: A randomized controlled trial (CONSORT compliant)
title_fullStr The effects of target-controlled infusion of lidocaine undergoing vocal cord polypectomy: A randomized controlled trial (CONSORT compliant)
title_full_unstemmed The effects of target-controlled infusion of lidocaine undergoing vocal cord polypectomy: A randomized controlled trial (CONSORT compliant)
title_short The effects of target-controlled infusion of lidocaine undergoing vocal cord polypectomy: A randomized controlled trial (CONSORT compliant)
title_sort effects of target-controlled infusion of lidocaine undergoing vocal cord polypectomy: a randomized controlled trial (consort compliant)
topic 3300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830819/
https://www.ncbi.nlm.nih.gov/pubmed/35147085
http://dx.doi.org/10.1097/MD.0000000000027642
work_keys_str_mv AT zhoulongyuan theeffectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT wuruilan theeffectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT caichang theeffectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT qiyong theeffectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT bixinghua theeffectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT hangqi theeffectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT zhoulongyuan effectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT wuruilan effectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT caichang effectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT qiyong effectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT bixinghua effectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant
AT hangqi effectsoftargetcontrolledinfusionoflidocaineundergoingvocalcordpolypectomyarandomizedcontrolledtrialconsortcompliant